Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Early Improvement in Clinical Status Following Ventricular Assist Device Implantation in Children: A Marker for Survival
Conway, Jennifer , Ravekes, William, McConnell, Patrick , Cantor, Ryan S. , Koehl, Devin, Sun, Benjamin , Daly, Richard C., Hsu, Daphne T. , Conway, Jennifer , Ravekes, William, McConnell, Patrick , Cantor, Ryan S. , Koehl, Devin, Sun, Benjamin C , Daly, Richard C., Hsu, Daphne T.

Mayo Clinic

ASAIO Journal | April 16, 2021 | Volume: 68 | Issue: 1 | Pages: 87-95

10.1097/mat.0000000000001420 | PMID 33852494 Get It

While clinical status at the time of ventricular assist device (VAD) implant can negatively affect outcomes, it is unclear if early improvement after implant can have a positive effect. Therefore, the objectives of this study were to describe the clinical status of pediatric patients supported with a VAD and determine the impact of clinical status on the 1-month follow-up form on survival and ability to discharge. This was a retrospective analysis of data collected prospectively by the Pediatric Interagency Registry for Mechanical Circulatory Support Registry (Pedimacs) Registry. The Pedimacs database was queried for patients implanted between September 19, 2012, and September 30, 2019, who were alive on VAD support at 1-month postimplant on either a paracorporeal pulsatile or intracorporeal continuous device. Four factors on the 1-month follow-up were the focus of this study: mechanical ventilation, supplemental nutritional support, inotropic support, and ambulatory status. These factors were regarded as present if detected between 1-week and 1-month postimplant and were analyzed to determine their impact on survival following 1 month of VAD support and on successful discharge from hospital in patients with implantable continuous-flow devices. The eligible study cohort consisted of 414 patients with a mean age of 9.6 ± 6.2 years, weight of 40.8 ± 32.3 kg with the majority being male (56.7%) and having cardiomyopathy (68%). An isolated left ventricular assist device (LVAD) was the most common implant (85.5%). At implant, 40% were ventilated, 57% required nutritional support, 93% were on inotropes, and 58% were nonambulating. On the 1-month postimplant form, there were significant improvements in all four categories (14% ventilator support, 46% nutritional support, 53% on inotropes, and 25% nonambulating). However, there was no significant early change in the percentage of patients requiring supplemental nutrition in the paracorporeal pulsatile devices (88% vs. 82%; p = 0.2). Presence of these clinical parameters in early follow-up postimplant had a significant negative impact on survival and on the ability of patients with continuous-flow devices to be discharged. Presence of four specific clinical parameters early after VAD placement is associated with worse overall survival and an inability to discharge patients on VAD support. Ongoing work is needed for optimization of patients before implant and aggressive rehabilitation after implant to help improve long-term outcomes.
Electronic Geriatric Assessment: Is It Feasible in a Multi-Institutional Study That Included a Notable Proportion of Older African American Patients? (Alliance A171603)
Guerard, Emily J., Dodge, Andrew , Le‐Rademacher, Jennifer , Kemeny, Margaret, Ojelabi, Michael, Sedrak, Mina S. , Hopkins, Judith O. , Shahrokni, Armin , Harlos, Elizabeth, Muss, Hyman B. , Cohen, Harvey Jay, Lafky, Jacqueline M., Sloan, Jeff A. , Jatoi, Aminah , Hurria, Arti , Dodge, Andrew B , Le-Rademacher, Jennifer G , Muss, Hyman , Lafky, Jacqueline, Sloan, Jeff , Ojelabi, Michael Olayiwola , Sedrak, Mina S.

Mayo Clinic

JCO Clinical Cancer Informatics | April 14, 2021 | Volume: No volume available | Issue: 5 | Pages: 435-441

10.1200/cci.20.00163 | PMID 33852323 Get It

PURPOSE This study determined whether an electronic version of the geriatric assessment is feasible in a multi-institutional, diverse setting. METHODs Ten sites within the Alliance for Clinical Trials in Oncology participated. Patients who had active cancer or a history of cancer and were 65 years of age or older were eligible. The geriatric assessment was completed with an electronic data capture system that had been loaded onto iPads. Feasibility was defined a priori as completion in at least 70% of patients either with or without help. To enhance racial diversity, the original sample size was later changed and augmented by 50% with the intention of increasing enrollment of older minority patients. RESULTS A total of one hundred fifty-four patients were registered with a median age of 72 years (range, 65-91 years). Forty-three (28%) identified themselves as African American or Black. One hundred forty-one patients (92%) completed the electronic geriatric assessment. Feasibility was observed across all subgroups, regardless of race, education, performance status, comorbidities, and cognition; 124 patients (81%) completed the geriatric assessment without help. Reasons for not completing the geriatric assessment are as follows: clinic visit did not occur (n = 6), no iPad connection to the Internet (n = 3), patient declined (n = 2), prolonged hospitalization (n = 1), and patient died (n = 1). Reasons for needing help, as reported by study personnel, were as follows: the patient preferred that research personnel ask the questions (n = 9), vision problem (n = 3), lack of comfort with the iPad (n = 2), questions were not clear (n = 1), less proficient in English (n = 1), and challenge in pressing the green button to go to the next question (n = 1). CONCLUSION The electronic geriatric assessment is feasible in a multi-institutional setting that includes a notable proportion of African American or Black patients.
Comparison of Chest CT Findings of COVID-19, Influenza, and Organizing Pneumonia: A Multireader Study
Garrana, Sherief , Som, Avik , Ndakwah, Gabrielle S., Yeung, Tristan, Febbo, Jennifer , Heeger, Allen , Lang, Min , McDermott, Shaunagh , Mendoza, Dexter P. , Zhang, Éric , Sharma, Amita , Little, Brent P. , Sharma, Amita , Yeung, Tristan, Narayan, Anand K.

Mayo Clinic

American Journal of Roentgenology | April 14, 2021 | Volume: 217 | Issue: 5 | Pages: 1093-1102

10.2214/ajr.21.25640 | PMID 33852360 Get It

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)
Broman, Kristy K. , Dossett, Lesly A. , Кириченко, Д. А. , Carr, Michael J. , Sharma, Avinash , Bartlett, Edmund K. , Nijhuis, Amanda A. G. , Kottschade, Lisa A. , Downs, Jennifer , Akkooi, Alexander C. J. van , Ollila, David W. , Frank, Jill S. , Karakousis, Giorgos C. , Nobes, Jenny , Vetto, John T. , Han, Dale , Farma, Jeffrey M. , Deneve, Jeremiah L. , Fleming, Martin D. , Bagge, Roger Olofsson , Lee, Ann Y. , Berman, Russell S. , Chai, Harvey , Kroon, Hidde M. , Teras, Jüri, Teras, Roland M., Hui, Jane Yuet Ching , Been, Lukas B. , Kruijff, Schelto , Naqvi, Syeda Mahrukh Hussnain , Sondak, Vernon K. , Broman, Kristy Kummerow , Kirichenko, Dennis , Bartlett, Edmund K , Hieken, Tina J , Kottschade, Lisa, Song, Yun , Karakousis, Giorgos , Lowe, Michael C , Hui, Jane Yuet Ching , Olofsson Bagge, Roger , Hughes, Tasha M. , Sun, James X. , Thompson, John F. , Hieken, Tina J. , Gyorki, David E. , Stahlie, Emma H. A. , Moncrieff, Marc D. , Perez, Matthew C , Mattsson, Jan , Farrow, Norma E. , Beasley, Georgia M. , Kim, Youngchul , Sarnaik, Amod A. , Zager, Jonathan S.

Mayo Clinic

Cancer | April 7, 2021 | Volume: 127 | Issue: 13 | Pages: 2251-2261

10.1002/cncr.33483 | PMID 33826754 Get It

BackgroundFor patients with sentinel lymph node (SLN)‐positive cutaneous melanoma, the Second Multicenter Selective Lymphadenectomy trial demonstrated equivalent disease‐specific survival (DSS) with active surveillance using nodal ultrasound versus completion lymph node dissection (CLND). Adoption and outcomes of active surveillance in clinical practice and in adjuvant therapy recipients are unknown.MethodsIn a retrospective cohort of SLN‐positive adults treated at 21 institutions in Australia, Europe, and the United States from June 2017 to November 2019, the authors evaluated the impact of active surveillance and adjuvant therapy on all‐site recurrence‐free survival (RFS), isolated nodal RFS, distant metastasis‐free survival (DMFS), and DSS using Kaplan‐Meier curves and Cox proportional hazard models.ResultsAmong 6347 SLN biopsies, 1154 (18%) were positive and had initial negative distant staging. In total, 965 patients (84%) received active surveillance, 189 (16%) underwent CLND. Four hundred thirty‐nine patients received adjuvant therapy (surveillance, 38%; CLND, 39%), with the majority (83%) receiving anti–PD‐1 immunotherapy. After a median follow‐up of 11 months, 220 patients developed recurrent disease (surveillance, 19%; CLND, 22%), and 24 died of melanoma (surveillance, 2%; CLND, 4%). Sixty‐eight patients had an isolated nodal recurrence (surveillance, 6%; CLND, 4%). In patients who received adjuvant treatment without undergoing prior CLND, all isolated nodal recurrences were resectable. On risk‐adjusted multivariable analyses, CLND was associated with improved isolated nodal RFS (hazard ratio [HR], 0.36; 95% CI, 0.15‐0.88), but not all‐site RFS (HR, 0.68; 95% CI, 0.45‐1.02). Adjuvant therapy improved all‐site RFS (HR, 0.52; 95% CI, 0.47‐0.57). DSS and DMFS did not differ by nodal management or adjuvant treatment.ConclusionsActive surveillance has been adopted for most SLN‐positive patients. At initial assessment, real‐world outcomes align with randomized trial findings, including in adjuvant therapy recipients.Lay Summary For patients with melanoma of the skin and microscopic spread to lymph nodes, monitoring with ultrasound is an alternative to surgically removing the remaining lymph nodes. The authors studied adoption and real‐world outcomes of ultrasound monitoring in over 1000 patients treated at 21 centers worldwide, finding that most patients now have ultrasounds instead of surgery. Although slightly more patients have cancer return in the lymph nodes with this strategy, typically, it can be removed with delayed surgery. Compared with up‐front surgery, ultrasound monitoring results in the same overall risk of melanoma coming back at any location or of dying from melanoma.
The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma
Chen, Zirong , Ni, Wei , Li, Jian‐Liang , Zhou, Xin , Li, Jennifer W. , Leon, Marino E. , Zolotukhin, Sergei, Lu, Jianrong , Griffin, James D. , Kaye, Frederic J. , Wu, Lizi , Lin, Shuibin , Sun, Yuping , Hurtado, Maria D. , Liu, Chen

Mayo Clinic

JCI Insight | April 7, 2021 | Volume: 6 | Issue: 7 | Pages: No page available

10.1172/jci.insight.139497 | PMID 33830080 Get It

No effective systemic treatment is available for patients with unresectable, recurrent, or metastatic mucoepidermoid carcinoma (MEC), the most common salivary gland malignancy. MEC is frequently associated with a t(11;19)(q14-21;p12-13) translocation that creates a CRTC1-MAML2 fusion gene. The CRTC1-MAML2 fusion exhibited transforming activity in vitro; however, whether it serves as an oncogenic driver for MEC establishment and maintenance in vivo remains unknown. Here, we show that doxycycline-induced CRTC1-MAML2 knockdown blocked the growth of established MEC xenografts, validating CRTC1-MAML2 as a therapeutic target. We further generated a conditional transgenic mouse model and observed that Cre-induced CRTC1-MAML2 expression caused 100% penetrant formation of salivary gland tumors resembling histological and molecular characteristics of human MEC. Molecular analysis of MEC tumors revealed altered p16-CDK4/6-RB pathway activity as a potential cooperating event in promoting CRTC1-MAML2–induced tumorigenesis. Cotargeting of aberrant p16-CDK4/6-RB signaling and CRTC1-MAML2 fusion–activated AREG/EGFR signaling with the respective CDK4/6 inhibitor Palbociclib and EGFR inhibitor Erlotinib produced enhanced antitumor responses in vitro and in vivo. Collectively, this study provides direct evidence for CRTC1-MAML2 as a key driver for MEC development and maintenance and identifies a potentially novel combination therapy with FDA-approved EGFR and CDK4/6 inhibitors as a potential viable strategy for patients with MEC.
Neuropathy Severity at the Time of Oxaliplatin Treatment Alteration in Patients with Colon Cancer (Alliance A151912)
Hertz, Daniel L. , Dockter, Travis , Satele, Daniel , Loprinzi, Charles L. , Hertz, Daniel L , Le‐Rademacher, Jennifer

Mayo Clinic

No container title available | April 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-300187/v1 Get It

Abstract Background: Clinical guidelines recommend altering chemotherapy treatment by decreasing, delaying, or discontinuing dosing in patients who are experiencing chemotherapy-induced peripheral neuropathy. There are few data available on the clinical use of treatment alteration including the severity of CIPN at the time of treatment alteration. Methods: This was a retrospective analysis of patients receiving oxaliplatin on the NCCTG N08CB trial. Neuropathy severity was assessed at each cycle by clinicians and patients. Patients were classified as 1) completed treatment without alteration, 2) dose reduction or delay due to neuropathy, 3) discontinuation due to neuropathy, or discontinuation for other toxicity (4), or another reason (5). Comparisons focused primarily on patients with alteration due to neuropathy (groups 2 and/or 3) compared with patients who completed treatment without alteration (group 1). Results: In 350 participants, 135 (39%) completed treatment without alteration, 70 (20%) had a dose reduction or delay due to neuropathy, and 35 (10%) discontinued early due to neuropathy. Clinician-assessed neuropathy severity was greater in patients at the time of dose reduction or delay compared with severity at the end of treatment in patients without alteration (p<0.0001). Patient-reported neuropathy severity at cycle 4 was worse in patients who had an alteration as compared with patients who completed treatment without alteration (p=0.017). Conclusions: Treatment alterations due to neuropathy are common in patients receiving oxaliplatin for colon cancer and are associated with clinician-assessed neuropathy severity. Rapid increases in patient-reported neuropathy severity indicate a potential need for monitoring and intervention.
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Lim, Bora , Potter, David A. , Silverman, Paula , Haddad, Tufia C. , Forget, Frédéric, Awada, Ahmad , Canon, Jean‐Luc, Danso, Michael A., Lortholary, Alain , Bourgeois, Hugues , Tan-Chiu, Elizabeth, Vincent, Sylvie , Bahamón, Brittany, Neuwirth, Rachel, Leonard, E. Jane , Diamond, Jennifer R. , Silverman, Paula , Haddad, Tufia C , Awada, Ahmad , Bourgeois, Hugues , Vincent, Sylvie , Galinsky, Kevin J , Potter, David A , Salkeni, Mohamad Adham , Canon, Jean-Luc Re , Patel, Chirag Amrutlal , Lim, Bora

Mayo Clinic

Clinical Cancer Research | April 5, 2021 | Volume: 27 | Issue: 12 | Pages: 3329-3338

10.1158/1078-0432.ccr-20-4131 | PMID 33820779 Get It

Abstract Purpose: This open-label, multicenter, phase IB/II study evaluated sapanisertib, a dual inhibitor of mTOR kinase complexes 1/2, plus exemestane or fulvestrant in postmenopausal women with hormone receptor–positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer. Patients and Methods: Eligible patients had previously progressed on everolimus with exemestane/fulvestrant and received ≤3 (phase IB) or ≤1 (phase II) prior chemotherapy regimens. Patients received sapanisertib 3 to 5 mg every day (phase IB), or 4 mg every day (phase II) with exemestane 25 mg every day or fulvestrant 500 mg monthly in 28-day cycles. Phase II enrolled parallel cohorts based on prior response to everolimus. The primary objective of phase II was to evaluate antitumor activity by clinical benefit rate at 16 weeks (CBR-16). Results: Overall, 118 patients enrolled in phase IB (n = 24) and II (n = 94). Five patients in phase IB experienced dose-limiting toxicities, at sapanisertib doses of 5 mg every day (n = 4) and 4 mg every day (n = 1); sapanisertib 4 mg every day was the MTD in combination with exemestane or fulvestrant. In phase II, in everolimus-sensitive versus everolimus-resistant cohorts, CBR-16 was 45% versus 23%, and overall response rate was 8% versus 2%, respectively. The most common adverse events were nausea (52%), fatigue (47%), diarrhea (37%), and hyperglycemia (33%); rash occurred in 17% of patients. Molecular analysis suggested positive association between AKT1 mutation status and best treatment response (complete + partial response; P = 0.0262). Conclusions: Sapanisertib plus exemestane or fulvestrant was well tolerated and exhibited clinical benefit in postmenopausal women with pretreated everolimus-sensitive or everolimus-resistant breast cancer.
Vaping and E-Cigarette Use in Children and Adolescents: Implications on Perioperative Care From the American Society of Anesthesiologists Committee on Pediatric Anesthesia, Society for Pediatric Anesthesia, and American Academy of Pediatrics Section on Ane
Rusy, Deborah A. , Honkanen, Anita , Landrigan‐Ossar, Mary, Chatterjee, Debnath , Schwartz, Lawrence , Lalwani, Kirk, Dollar, Jennifer, Clark, R. Lee , Diaz, Christina D. , Soriano, Sulpicio G. , Clark, Randall, Deutsch, Nina , Warner, David O.

Mayo Clinic

Anesthesia & Analgesia | March 29, 2021 | Volume: 133 | Issue: 3 | Pages: 562-568

10.1213/ane.0000000000005519 | PMID 33780391 Get It

Electronic cigarettes (e-cigarettes) or vaping use in adolescents has emerged as a public health crisis that impacts the perioperative care of this vulnerable population. E-cigarettes have become the most commonly used tobacco products among youth in the United States. Fruit and mint flavors and additives such as marijuana have enticed children and adolescents. E-cigarette, or vaping, product use–associated lung injury (EVALI) is a newly identified lung disease linked to vaping. Clinical presentation of EVALI can be varied, but most commonly includes the respiratory system, gastrointestinal (GI) tract, and constitutional symptoms. Clinical management of EVALI has consisted of vaping cessation and supportive therapy, including supplemental oxygen, noninvasive ventilation, mechanical ventilation, glucocorticoids, and empiric antibiotics, until infectious causes are eliminated, and in the most severe cases, extracorporeal membrane oxygenation (ECMO). Currently, although there is an insufficient evidence to determine the safety and the efficacy of e-cigarettes for perioperative smoking cessation, EVALI clearly places these patients at an increased risk of perioperative morbidity. Given the relatively recent introduction of e-cigarettes, the long-term impact on adolescent health is unknown. As a result, the paucity of postoperative outcomes in this potentially vulnerable population does not support evidence-based recommendations for the management of these patients. Clinicians should identify “at-risk” individuals during preanesthetic evaluations and adjust the risk stratification accordingly. Our societies encourage continued education of the public and health care providers of the risks associated with vaping and nicotine use and encourage regular preoperative screening and postoperative outcome studies of patients with regard to smoking and vaping use.
Patterns of Functional Change Five to Ten Years after Moderate-Severe Traumatic Brain Injury
Malec, James F. , Whiteneck, Gale G. , Hart, Tessa , Novack, Thomas A. , Bogner, Jennifer , Dahdah, Marie N. , Eagye, C.B. , Sevigny, Mitch , Ketchum, Jessica M. , Hammond, Flora M. , Corrigan, John D. , Dams-O’Connor, Kristen

Mayo Clinic

Journal of Neurotrauma | March 27, 2021 | Volume: 38 | Issue: 11 | Pages: 1526-1534

10.1089/neu.2020.7499 | PMID 33779295 Get It

This study aims to characterize the patterns of functional change experienced between 5 and 10 years after moderate-severe traumatic brain injury (TBI). The study included TBI Model Systems national database participants ( N = 372) at six sites who experienced TBI, received inpatient rehabilitation, and were followed at 5 and 10 years post-TBI. Outcome measures included self- or proxy-reported Functional Independence Measure (FIM TM ) structured interview at 5 and 10 years post-TBI and domain change indices (DCIs) at 10 years to assess subjective change over the previous 5 years. When all seven FIM and subjective DCI subscales were considered together, 69% reported improvement in at least one subscale and 41% reported decline in at least one subscale; 51% reported more domains improved than declined, and 20% reported more domains declined than improved. Age at injury, post-traumatic amnesia duration, FIM, and depression and anxiety at year 5 were associated with FIM change and DCI measures. Although most persons with moderate-severe TBI do not experience widespread change from year 5 to 10 on individual FIM subscales or perceived domain-specific subscales, the vast majority do report change in one or more domains, with more improvement than decline and more change in subjective DCI than in FIM. Clinicians and researchers should be alert to the possibility of both positive and deleterious changes many years after TBI.
Current Parental Leave Policies for Medical Students at U.S. Medical Schools: A Comparative Study
Kraus, Molly B. , Talbott, Jennifer , Melikian, Ryan, Merrill, Sarah , Stonnington, Cynthia M. , Files, Julia A. , Kouloumberis, Pelagia , Talbott, Jennifer M V, Merrill, Sarah A, Kouloumberis, Pelagia E, Kraus, Molly B , Talbott, Jennifer M V , Hayes, Sharonne N.

Mayo Clinic

Academic Medicine | March 26, 2021 | Volume: 96 | Issue: 9 | Pages: 1315-1318

10.1097/acm.0000000000004074 | PMID 33769337 Get It

Purpose Parental leave for new parents is essential as they adjust to the physical and psychological changes that accompany childbirth and caring for a newborn. This study sought to determine the current state of parental leave policies for medical students at medical schools in the United States. Method From November to December 2019, 2 researchers independently reviewed the websites of 199 U.S. MD-granting and DO-granting medical schools (including in U.S. territories). Online student handbooks and school webpages were searched for the following keywords: “pregnant” OR “pregnancy” OR “maternity” OR “parent” OR “family” OR “child” OR “birth.” Data were analyzed using descriptive statistics. Fisher’s exact tests evaluated differences in proportion by group. Results Of 199 schools, 65 (32.66%) had parental leave policies available online or in the handbook: 39 of 155 (25.16%) MD-granting and 26 of 44 (59.09%) DO-granting schools. Of those policies, 59 (90.77%) were included in the student handbook. Most policies (28, 43.08%) were included as an option within the school’s general leave of absence policy. Both parents were included in 38 (58.46%) policies; 23 (35.38%) policies mentioned only mothers; and 4 (6.15%) were unknown. An option to maintain original graduation date was offered in 21 (32.1%) schools’ policies. Three schools (4.62%) included adoption as qualifying for parental leave. When comparing MD and DO programs, DO programs were statistically more likely to have a parental leave policy: 39 (25.16%) vs 26 (59.09%); P < .001. Conclusions Balancing medical school with pregnancy and childbirth necessitates administrative support to address the inherent scheduling challenges. Currently, many schools lack parental leave policies for medical students that are easily accessible, are separate from formal leaves of absence, allow for at least 12 weeks, and are tailored to the student academic year to ensure on-time completion of medical education.